Karo Bio Receives US Patent for New Methods of Treating Skin Disorders

Apr 25, 2001, 01:00 ET from Karo Bio

    HUDDINGE, Sweden, April 25 /PRNewswire/ -- Karo Bio announced today that
 the company has received a US patent for methods to treat certain skin
 disorders.  This patent provides broad coverage including method-of-treatment
 claims as well as claims for skin treatment compositions with thyroid hormone
 as well as analogs of thyroid hormone.
     Previously, Karo Bio has carried out animal studies that demonstrated
 desirable effects of thyroid hormone and thyroid hormone analogs upon the
 composition of treated skin.  These studies also demonstrated that these
 compounds blocked the negative effects of anti-inflammatory steroids upon skin
 composition.  The Company believes that the treatment of certain skin diseases
 with thyroid hormone analogs has considerable advantages over other treatments
 such as those with vitamin A analogs.
     Karo Bio has recently finished two clinical studies in the dermatology
 area and reports are being prepared.
     "We are very happy about the US issuance of our skin treatment patent says
 Per Otteskog, Acting President at Karo Bio.  "The skin is the largest organ in
 the body and can be affected by a number of different diseases where today's
 methods of treatment are insufficient.  As a first therapeutic indication we
 have chosen steroid induced skin atrophy but we also intend to follow up with
 additional therapeutic indications.  We consider this to be an area with
 substantial potential."
 
     For further information contact:
 
     Karo Bio AB
     Per Otteskog, Acting President, Karo Bio
     Direct telephone: +46-8-608 6018
     Mobile telephone: +46-70-632 7527
 
     Background
 
     Karo Bio is a company with operations in the United States and Sweden.
 The Company employs 120 people and has 250 patent cases including 100 approved
 patents.
     Karo Bio has been listed on the Stockholm stock exchange (KARO) since 1998
 and has a leading position in the field of drug discovery and nuclear
 receptors.  Nuclear receptors are important and validated drug targets for a
 number of clinical indications and the Company uses proprietary technologies
 for the development of novel and improved therapies for major markets.  An
 important base for generation of new therapeutic strategies is Karo Bio's
 strong academic network.
     Karo Bio has drug discovery programs in therapeutic areas such as women's
 health care, metabolic disorders, cardiovascular disease, diabetes,
 dermatology, ophthalmology and infectious disease.
     Karo Bio collaborates with major pharmaceutical companies for development
 of products through clinical trials and marketing.  In these partnerships Karo
 Bio receives downpayments, R&D funding and royalties on net sales when
 products reach the market.
     Karo Bio's product pipeline is strong and includes a number of proprietary
 projects that will be partnered in different stages.  Karo Bio generally
 collaborates with major pharmaceutical companies from early drug discovery
 through clinical trials but also takes the opportunity to bring products to
 the clinic before partnering.  Apart from financial compensations the partners
 bring competence and resources for drug development and marketing to the
 collaboration.
     Karo Bio has one product in clinical trials and expects to enter clinical
 trials with partners in the future.
     Karo Bio has a strong financial position and its partnerships include
 Abbott Laboratories, Bristol-Myers Squibb, Merck & Co., Aventis Pharma, Bayer
 AG, Boehringer Ingelheim Pharmaceuticals, Inc. GPC Biotech, NovImmune S.A.,
 and Serono International S.A.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X53372514
 
 

SOURCE Karo Bio
    HUDDINGE, Sweden, April 25 /PRNewswire/ -- Karo Bio announced today that
 the company has received a US patent for methods to treat certain skin
 disorders.  This patent provides broad coverage including method-of-treatment
 claims as well as claims for skin treatment compositions with thyroid hormone
 as well as analogs of thyroid hormone.
     Previously, Karo Bio has carried out animal studies that demonstrated
 desirable effects of thyroid hormone and thyroid hormone analogs upon the
 composition of treated skin.  These studies also demonstrated that these
 compounds blocked the negative effects of anti-inflammatory steroids upon skin
 composition.  The Company believes that the treatment of certain skin diseases
 with thyroid hormone analogs has considerable advantages over other treatments
 such as those with vitamin A analogs.
     Karo Bio has recently finished two clinical studies in the dermatology
 area and reports are being prepared.
     "We are very happy about the US issuance of our skin treatment patent says
 Per Otteskog, Acting President at Karo Bio.  "The skin is the largest organ in
 the body and can be affected by a number of different diseases where today's
 methods of treatment are insufficient.  As a first therapeutic indication we
 have chosen steroid induced skin atrophy but we also intend to follow up with
 additional therapeutic indications.  We consider this to be an area with
 substantial potential."
 
     For further information contact:
 
     Karo Bio AB
     Per Otteskog, Acting President, Karo Bio
     Direct telephone: +46-8-608 6018
     Mobile telephone: +46-70-632 7527
 
     Background
 
     Karo Bio is a company with operations in the United States and Sweden.
 The Company employs 120 people and has 250 patent cases including 100 approved
 patents.
     Karo Bio has been listed on the Stockholm stock exchange (KARO) since 1998
 and has a leading position in the field of drug discovery and nuclear
 receptors.  Nuclear receptors are important and validated drug targets for a
 number of clinical indications and the Company uses proprietary technologies
 for the development of novel and improved therapies for major markets.  An
 important base for generation of new therapeutic strategies is Karo Bio's
 strong academic network.
     Karo Bio has drug discovery programs in therapeutic areas such as women's
 health care, metabolic disorders, cardiovascular disease, diabetes,
 dermatology, ophthalmology and infectious disease.
     Karo Bio collaborates with major pharmaceutical companies for development
 of products through clinical trials and marketing.  In these partnerships Karo
 Bio receives downpayments, R&D funding and royalties on net sales when
 products reach the market.
     Karo Bio's product pipeline is strong and includes a number of proprietary
 projects that will be partnered in different stages.  Karo Bio generally
 collaborates with major pharmaceutical companies from early drug discovery
 through clinical trials but also takes the opportunity to bring products to
 the clinic before partnering.  Apart from financial compensations the partners
 bring competence and resources for drug development and marketing to the
 collaboration.
     Karo Bio has one product in clinical trials and expects to enter clinical
 trials with partners in the future.
     Karo Bio has a strong financial position and its partnerships include
 Abbott Laboratories, Bristol-Myers Squibb, Merck & Co., Aventis Pharma, Bayer
 AG, Boehringer Ingelheim Pharmaceuticals, Inc. GPC Biotech, NovImmune S.A.,
 and Serono International S.A.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X53372514
 
 SOURCE  Karo Bio